BR112013013636A2 - processos para o tratamento de doenças da retina - Google Patents

processos para o tratamento de doenças da retina

Info

Publication number
BR112013013636A2
BR112013013636A2 BR112013013636A BR112013013636A BR112013013636A2 BR 112013013636 A2 BR112013013636 A2 BR 112013013636A2 BR 112013013636 A BR112013013636 A BR 112013013636A BR 112013013636 A BR112013013636 A BR 112013013636A BR 112013013636 A2 BR112013013636 A2 BR 112013013636A2
Authority
BR
Brazil
Prior art keywords
processes
retinal diseases
treating retinal
treating
diseases
Prior art date
Application number
BR112013013636A
Other languages
English (en)
Portuguese (pt)
Inventor
Daniel W Gil
Edwin U Padillo
Jyotirmoy X Kusari
Larry A Wheeler
Mingting Tian
Sandhya S Rao
Sheila X Zhou
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BR112013013636A2 publication Critical patent/BR112013013636A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112013013636A 2010-12-03 2011-11-18 processos para o tratamento de doenças da retina BR112013013636A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41966010P 2010-12-03 2010-12-03
PCT/US2011/061370 WO2012074788A1 (en) 2010-12-03 2011-11-18 Methods for treating diseases of the retina

Publications (1)

Publication Number Publication Date
BR112013013636A2 true BR112013013636A2 (pt) 2016-11-08

Family

ID=45507856

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013013636A BR112013013636A2 (pt) 2010-12-03 2011-11-18 processos para o tratamento de doenças da retina

Country Status (10)

Country Link
US (2) US9018202B2 (https=)
EP (1) EP2646034A1 (https=)
JP (1) JP2013544838A (https=)
KR (1) KR20130122958A (https=)
CN (1) CN103327981A (https=)
AU (1) AU2011336976A1 (https=)
BR (1) BR112013013636A2 (https=)
CA (1) CA2819616A1 (https=)
RU (1) RU2013129748A (https=)
WO (1) WO2012074788A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10752593B2 (en) 2018-12-28 2020-08-25 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
JP6864327B2 (ja) 2017-07-06 2021-04-28 山田　健一 脂質過酸化誘発性疾患の治療薬およびそのスクリーニング方法
US10807973B2 (en) 2018-12-28 2020-10-20 Endogena Therapeutics, Inc. Compounds for use as therapeutically active substances in the treatment of retinal diseases
EP3919052A4 (en) * 2019-01-09 2022-10-05 Fuso Pharmaceutical Industries, Ltd. Pharmaceutical composition for intraocular or oral administration for treatment of retinal diseases
US20250170143A1 (en) * 2022-04-14 2025-05-29 Mayo Foundation For Medical Education And Research Methods of treating ocular fibrotic pathologies

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1004520A1 (en) 1992-05-13 1998-11-27 Novartis Ag Ophthalmic compositions containing a cyclosporin
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
US5631250A (en) 1995-03-24 1997-05-20 Eli Lilly And Company Process and solvate of 2-methyl-thieno-benzodiazepine
US5744468A (en) * 1996-10-23 1998-04-28 Tong-Ho Lin Hypotensive intraocular pressure activity of clozapine and sulpiride
JPH10175865A (ja) * 1996-12-11 1998-06-30 Towa Rin 抗眼圧活性製剤
US7160898B2 (en) * 2001-12-14 2007-01-09 Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
JP2002530340A (ja) * 1998-11-23 2002-09-17 セプラコール， インク． オランザピン−ｎ−オキサイドを含む医薬組成物
DE10206941A1 (de) 2002-02-19 2003-09-25 Goetz Nowak Neue Arzneimittel
JP2006515628A (ja) * 2003-01-23 2006-06-01 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神疾患を処置するためのｎ−デスメチルクロザピンの使用
WO2004103263A2 (en) 2003-05-22 2004-12-02 Yeda Research And Development Co. Ltd. Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
US20050059583A1 (en) 2003-09-15 2005-03-17 Allergan, Inc. Methods of providing therapeutic effects using cyclosporin components
US20050277584A1 (en) 2004-06-09 2005-12-15 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US20060035887A1 (en) 2004-07-02 2006-02-16 Dr. Reddy's Laboratories Limited Process for preparing olanzapine
AU2005271513A1 (en) * 2004-08-05 2006-02-16 Acadia Pharmaceuticals Inc. Use of N-desmethylclozapine to treat human neuropsychiatric disease
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
MX2007003789A (es) 2004-10-04 2007-07-20 Qlt Usa Inc Suministro ocular de formulaciones polimericas para suministro.
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US20070015691A1 (en) 2005-07-13 2007-01-18 Allergan, Inc. Cyclosporin compositions
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
CN101711236B (zh) * 2007-04-12 2012-10-31 Nsab神经研究瑞典公司分公司 表现出改善的心血管副作用特性的多巴胺受体稳定剂/调节剂的n-氧化物和/或二-n-氧化物衍生物

Also Published As

Publication number Publication date
CN103327981A (zh) 2013-09-25
US9018202B2 (en) 2015-04-28
CA2819616A1 (en) 2012-06-07
AU2011336976A1 (en) 2013-07-11
JP2013544838A (ja) 2013-12-19
US9561234B2 (en) 2017-02-07
EP2646034A1 (en) 2013-10-09
RU2013129748A (ru) 2015-01-10
WO2012074788A1 (en) 2012-06-07
KR20130122958A (ko) 2013-11-11
US20150290215A1 (en) 2015-10-15
US20120142675A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
LTC2785706I2 (lt) Pakeistieji 4-fenil-piridinai, skirti su nk-receptoriumi susijusių ligų gydymui
BR112013007678A2 (pt) método para tratamento de doenças alérgicas
IL229257A0 (en) Preparations and methods for the treatment of diseases related to the retina of the eye
CO7061081A2 (es) Derivados macrocíclicos para el tratamiento de enfermedades
PT2877184T (pt) Composições e tratamento para doenças e distúrbios oculares
DK2701697T3 (da) Oxidative nethindesygdomme
EP2766044A4 (en) TREATMENT OF EYE DISEASES
IL260714B (en) Methods for the treatment and diagnosis of blinding eye diseases
SG2014008080A (en) Methods of treatment of retinal degeneration diseases
CO6940374A2 (es) Composiciones, usos y métodos para tratamiento de trastornos y enfermedades metabólicas
ZA201408592B (en) Methods for the treatment of diabetic retinopathy and other ophthalmic diseases
BR112013024169A2 (pt) método para o tratamento e prevenção da doença de parkinson
BRPI1013377A2 (pt) formulação de quinonas de tocotrienol para o tratamento de doenças oftálmicas
BR112014004306A2 (pt) fotossensibilizadores de (bacterio)clorofila para tratamento de doenças e distúrbios do olho
ZA201309557B (en) Methods of treatment for retinal diseases
IL230960A0 (en) A device for the treatment of eye disease
EP2558104A4 (en) METHOD AND OPHTHALMIC COMPOSITION FOR TREATING RETINAL DISEASE
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
PT2525796T (pt) Solução aquosa incluindo 3-quinuclidinonas para o tratamento de doenças hiperproliferativas, auto-imunes e cardíacas
BR112013009701A2 (pt) regimes de dosagem para o tratamento de doença vascular ocular
IL230959B (en) A device for the treatment of eye disease
BR112013013636A2 (pt) processos para o tratamento de doenças da retina
EP2554163A4 (en) THERAPEUTIC ACTIVE FOR NEURODEGENERATIVE DISEASES
PT2904009T (pt) Compostos para o tratamento do bloqueio da remielinização em doenças associadas com a expressão da proteína do invólucro de herv-w
PT3377061T (pt) Mirabegron para o tratamento de doenças da retina

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]